John Maraganore, City Therapeutics executive chair
October 8, 2024 11:40 AM EDTUpdated 12:19 PM
Financing
Startups

John Maraganore's RNAi biotech City Ther­a­peu­tics de­buts with $135M Se­ries A

Ayisha Sharma

News Reporter

City Ther­a­peu­tics has launched with $135 mil­lion and Al­ny­lam’s for­mer CEO lead­ing the charge as it de­vel­ops a pipeline of next-gen­er­a­tion RNAi ther­a­pies that could …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er's for­mer top ex­ec­u­tives pitched changes to board as part of ac­tivist's plan

Ex­clu­sive: A small San Diego biotech wants to change how Parkin­son’s dis­ease is di­ag­nosed

Sage faces third study fail in six months as Alzheimer's can­di­date miss­es Phase 2 goal

Ex­clu­sive: Tiny start­up with big vi­sion to ex­tend healthspan by 20 years says it dis­cov­ered an ‘At­las of ...

Astel­las places new bet on gene ther­a­py in $50M up­front deal with UK start­up

Ex­clu­sive: Lil­ly backs a16z-fund­ed Ar­da Ther­a­peu­tic­s' $43M Se­ries A to take AD­Cs in­to fi­bro­sis

A service from the Financial Times